Civeoの空売り状況は、投資家がCiveoの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Civeo (NYSE:CVEO) 株価情報, 空売り情報

Civeo

Civeo Corp provides hospitality services to the natural resources industry in Canada, Australia and the United States. The company provides a full suite of services for guests, including lodging, catering and food service, housekeeping and maintenance at accommodation facilities that the company or its customers own. The company provides services that support the day-to-day operations of these facilities, such as laundry, facility management and maintenance, water and wastewater treatments, power generation, communication systems, security and logistics. The company operates in active oil, metallurgical coal, liquefied natural gas and iron ore-producing regions. The company operates in three reportable business segments Canada, Australia and the United States.

Civeo Corp

The new contract will incorporate catering and retail services; village, mine and port site cleaning services; facilities maintenance; and the provision of health and wellbeing solutions.
It is anticipated the six-year contract will generate approximately A$1.4B in revenues over the 2025-2030 contract period. Civeo has been operating the four additional villages under a Limited Notice To Proceed agreement since the second quarter of 2024.

News

CVEO

Reported Earlier, Civeo Renews A$1.4B Integrated Services Contract With Broader Scope In Australia

Civeo's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) short percent of float has fallen 13.33% since its last report. The company recently reported that it has 61 thousand shares sold short, which is 0.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Civeo Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736434818_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Civeo has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Civeo's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Civeo's peer group average for short interest as a percentage of float is 4.71%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(CVEO) - Analyzing Civeo's Short Interest

Civeo's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) short percent of float has fallen 21.88% since its last report. The company recently reported that it has 70 thousand shares sold short, which is 0.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.11 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Civeo Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733230819_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Civeo has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Civeo's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Civeo's peer group average for short interest as a percentage of float is 4.52%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Civeo?

WIIM

Civeo shares are trading lower after the company reported worse-than-expected Q3 EPS results.

Guidance

Civeo Sees FY24 Revenue $675M-$700M, Adjusted EBITDA $83M-$88M, Maintains Capital Expenditures Guidance $30M-$35M

Earnings

Earnings Beats

Earnings Misses

Civeo Q3 2024 GAAP EPS $(0.36) Misses $(0.02) Estimate, Sales $176.3M Beat $168.755M Estimate

<ul>
<li>Civeo&nbsp;announced today that its Board of Directors has renewed its share repurchase authorization for the Company to repurchase up to&nbsp;5%&nbsp;of its total common shares outstanding over the next twelve months.</li>
<li>Civeo may repurchase shares through open market repurchases and/or privately negotiated transactions, and intends to fund repurchases through cash on hand and cash generated from operations.</li>
</ul>

Buybacks

Reported Earlier, Civeo Renews Share Repurchase Authorization For Up To 5% Of Outstanding Shares

As of Aug 15, 2024, three stocks in the industrials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the<a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Heico Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>)</h3>
<ul>
<li>On Aug. 26 after the NYSE closing, HEICO will release its financial results for the third quarter ended July 31. The company's stock gained around 5% over the past month and has a <a href="https://www.benzinga.com/quote/HEI">52-week high of $242.98</a>.</li>
<li>RSI Value: 71.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>HEI Price Action: Shares of Heico gained 0.8% to close at $236.89 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Civeo Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>)</h3>
<ul>
<li>On Aug. 13, Civeo announced amendment and extension to its credit agreement, upsizing total revolving credit facility capacity from $200 million to $245 million. The company's stock gained around 16% over the past month and <a href="https://www.benzinga.com/quote/CVEO">has a 52-week high</a> of $28.25.</li>
<li>RSI Value: 75.08</li>
<li>CVEO Price Action: Shares of Civeo fell 0.4% to close at $27.65 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Axon Enterprise Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>)</h3>
<ul>
<li>On Aug. 6, Axon Enterprise reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates. The company's stock gained around 20% over the past month and has a <a href="https://www.benzinga.com/quote/AXON">52-week high</a> of $375.95.</li>
<li>RSI Value: 74.75</li>
<li>AXON Price Action: Shares of Axon Enterprise gained 0.4% to close at $370.57 on Wednesday.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40368892/jim-cramer-avoid-middle-market-plays-like-golub-capital-buy-mueller-industries-it-is-fan">Jim Cramer: &#8216;Avoid Middle Market Plays&#8217; Like Golub Capital, Buy Mueller Industries — &#8216;It Is Fantastic&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

AXON

Top 3 Industrials Stocks That May Implode In Q3

Financing

Civeo Corporation Announces Amendment And Extension To Its Credit Agreement, Upsizing Total Revolving Credit Facility Capacity From $200M To $245M

Stifel analyst Stephen Gengaro reiterates Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) with a Buy and raises the price target from $31 to $32.

Price Target

Reiteration

Analyst Ratings

Stifel Reiterates Buy on Civeo, Raises Price Target to $32

For the full year of 2024, Civeo is maintaining its previously provided revenue and Adjusted EBITDA&nbsp;guidance&nbsp;ranges of&nbsp;$625 million&nbsp;to&nbsp;$700 million&nbsp;and&nbsp;$80 million&nbsp;to&nbsp;$90 million, respectively. The Company is also maintaining its full year 2024 capital expenditure&nbsp;guidance&nbsp;of&nbsp;$30 million&nbsp;to&nbsp;$35 million.

Civeo Is Maintaining Previously Provided FY24 Revenue Guidance Range Of $625M-$700M Vs. $665.18M Estimate

Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.21 by 166.67 percent. This is a 86.67 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $188.71 million which beat the analyst consensus estimate of $173.70 million by 8.64 percent. This is a 5.52 percent increase over sales of $178.84 million the same period last year.

Civeo Q2 GAAP EPS $0.56 Beats $0.21 Estimate, Sales $188.71M Beat $173.70M Estimate

Fraser brings extensive U.S., Canadian and international executive management experience
Al Schoening to retire after 13-year career at Civeo
Civeo Corporation ("Civeo" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) today announced the appointment of Andrew "Andy" S. Fraser, a dynamic and experienced leader, as President, Canada, effective August 19, 2024. He succeeds Al Schoening, Senior Vice President, Canada, who will retire after serving 13 years at Civeo. Mr. Schoening will work closely with Mr. Fraser to ensure a smooth transition and is expected to remain a consultant for the Company for a period after his retirement.

Management

Civeo Appoints Andrew "Andy" S. Fraser As President, Canada, Effective August 19, 2024

Civeo Corporation Announced The Appointment Of E. Collin Gerry As The New Senior Vice President, Chief Financial Officer And Treasurer, Effective August 1, 2024, Replacing The Interim CEO Barclay Brewer

Peter McCann, SVP at Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>), executed a substantial insider sell on May 1, according to an SEC filing.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001590584/000159058424000081//Archives/edgar/data/1590584/000159058424000081/0001590584-24-000081-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, McCann sold 5,220 shares of Civeo. The total transaction value is $123,975.
At Wednesday morning, Civeo shares are down by 1.16%, trading at $22.95.
<h3>Discovering Civeo: A Closer Look</h3>
Civeo Corp provides hospitality services to the natural resources industry in Canada, Australia and the United States. The company provides a full suite of services for guests, including lodging, catering and food service, housekeeping and maintenance at accommodation facilities that the company or its customers own. The company provides services that support the day-to-day operations of these facilities, such as laundry, facility management and maintenance, water and wastewater treatments, power generation, communication systems, security and logistics. The company operates in active oil, metallurgical coal, liquefied natural gas and iron ore-producing regions. The company operates in three reportable business segments Canada, Australia and the United States.
<h3>Civeo: Financial Performance Dissected</h3>
Revenue Growth: Civeo's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -0.88%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: With a low gross margin of 21.48%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Civeo's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of -0.35.
</li>
</ul>
Debt Management: Civeo's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.3.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 11.16 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 0.49, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 3.32, Civeo presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001590584">Check Out The Full List Of Civeo's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Civeo SVP Trades $123K In Company Stock

Stifel analyst Stephen Gengaro maintains Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) with a Buy and raises the price target from $30 to $31.

Stifel Maintains Buy on Civeo, Raises Price Target to $31

Shares of Clever Leaves Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLVR#NASDAQ">CLVR</a>) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister its Securities to terminate and suspend its reporting obligations.
Clever Leaves Holdings shares dipped 60% to $1.6498 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Deciphera Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCPH#NASDAQ">DCPH</a>) shares climbed 73% to $25.36 after the company announced it will be acquired by ONO Pharmaceutical for $25.60 per share in cash.</li>
<li>Collective Audience, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAUD#NASDAQ">CAUD</a>) gained 50.4% to $0.6002 after the company announced a strategic partnership with Insticator.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) shares gained 36.3% to $10.02. ImmunityBio shares jumped around 44% on Friday after the company announced overall survival results in its QUILT 3.055 study.</li>
<li>Koninklijke Philips N.V.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) shares climbed 35.5% to $28.56 after the company announced $1.1 billion settlement for Respironics personal injury and medical monitoring litigation. The company also reported better than expected first-quarter earnings and reaffirmed guidance.</li>
<li>Soleno Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) gained 31.1% to $49.66 after the company announced it received Breakthrough Therapy Designation from the FDA for DCCR extended-release tablets in Prader-Willi Syndrome.</li>
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) gained 25% to $3.9414 after the company announced the California Air Resources Board has approved the 2024 Mullen THREE for the Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project.</li>
<li>Enlivex Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLV#NASDAQ">ENLV</a>) climbed 25% to $1.7990.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) rose 23.9% to $6.06 after the company announced the publication of a scientific paper in a peer-reviewed journal that reinforces the rationale for inhibiting ASC with IC 100 to potentially attenuate cardiac comorbidities in patients with Alzheimer&#8217;s Disease.</li>
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) gained 23.8% to $2.25. HWH International recently announced that it entered into a joint venture to build its travel business in Asia.</li>
<li>Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSSE#NASDAQ">CSSE</a>) jumped 22% to $0.2948.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) rose 20.7% to $7.53.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) gained 19% to $1.0250.</li>
<li>Inno Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INHD#NASDAQ">INHD</a>) rose 17.8% to $0.7403.</li>
<li>Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) gained 17.7% to $14.98. Zoetis announced plans to sell its medicated feed additive portfolio to Phibro Animal Health for $350 million.</li>
<li>Heartland Financial USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTLF#NASDAQ">HTLF</a>) gained 17.2% to $41.86 after UMB Financial announced it will acquire the company.</li>
<li>Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) rose 14.6% to $50.08.</li>
<li>Arcadium Lithium plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NYSE">ALTM</a>) climbed 14.3% to $4.4350. Shares of lithium stocks traded higher, possibly on reports indicating Saudi Arabia is looking to obtain lithium from abroad for its EV efforts.</li>
<li>MultiPlan Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>) gained 14% to $0.6566. MultiPlan said it will release its first quarter 2024 financial results on Wednesday, May 8.</li>
<li>Prime Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) rose 11.2% to $4.9182 on FDA clearance of its IND application for PM359.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares gained 10.5% to $185.94 on reports the company will partner with Baidu for mapping and navigation for Full Self-Driving in China.</li>
<li>Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) rose 10.7% to $28.02. Cullinan Therapeutics announced appointment of Mary Kay Fenton as Chief Financial Officer.</li>
<li>Fulton Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULT#NASDAQ">FULT</a>) jumped 9.3% to $17.07. Republic First Bancorp has been seized by U.S. regulators and sold to Fulton Bank, a unit of Fulton Financial Corp.</li>
<li>Ocugen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) gained 8.2% to $1.3850.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Annovis Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NASDAQ">ANVS</a>) dipped 57% to $7.72 after the company announced data from its Phase II/III Alzheimer study of buntanetap in mild to moderate Alzheimer&#8217;s. Efficacy in the CGIC endpoint was not reached due to the limited number of patients and short trial duration.</li>
<li>Addex Therapeutics Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) fell 48.8% to $8.25 after the company announced the Phase 2 ADX71149 epilepsy study did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care.</li>
<li>mF International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFI#NASDAQ">MFI</a>) shares declined 30.3% to $1.6101 after dipping around 78% on Friday.</li>
<li>Avenue Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) fell 21.8% to $4.8440 after the company announced the exercise of warrants for $4.4 million in gross proceeds.</li>
<li>China Jo-Jo Drugstores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJJD#NASDAQ">CJJD</a>) dipped 21% to $2.29 after the company announced a $1.53 million registered direct offering.</li>
<li>Assure Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) fell 19.5% to $0.56 after the company said the unaudited financial statements for the quarterly periods ended March 31, 2023, June 30, 2023 and Sept 30, 2023 should no longer be relied on.</li>
<li>iSun, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISUN#NASDAQ">ISUN</a>) fell 19% to $0.1399. iSun, last week, announced rescission of reverse stock split.</li>
<li>Nature Wood Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWGL#NASDAQ">NWGL</a>) shares fell 18.8% to $4.10 after tumbling 70% on Friday.</li>
<li>Top KingWin Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCJH#NASDAQ">TCJH</a>) fell 18% to $0.7301.</li>
<li>STRATA Skin Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) dipped 17.3% to $0.43. The company announced a 1-for-10 reverse stock split.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) fell 16.5% to $6.68.</li>
<li>Flora Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) declined 15.6% to $1.1492.</li>
<li>Lifezone Metals Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LZM#NYSE">LZM</a>) fell 15.3% to $7.00.</li>
<li>NuZee, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) shares fell 13.5% to $1.41 after jumping 34% on Friday.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) fell 10.4% to $3.0550. Wedbush analyst Alicia Reese reiterated AMC with a Neutral and maintained a $4 price target.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares declined 10.1% to $1.3493 after declining over 5% on Friday.</li>
<li>SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) fell 9.9% to $7.09 following first-quarter results.</li>
<li>Hope Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOPE#NASDAQ">HOPE</a>) dipped 9.7% to $9.90 after the company reported worse-than-expected first-quarter financial results and signed a definitive merger with Territorial Bancorp.</li>
<li>Daqo New Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) shares declined 9.3% to $21.55 after the company missed first-quarter EPS and sales estimates.</li>
<li>Deutsche Bank Aktiengesellschaft (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>) fell 9.1% to $16.16 after the company disclosed it estimates it could have to pay up to €1.3 billion related to its Postbank litigation.</li>
<li>Altimmune, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) fell 9.4% to $6.58 after Guggenheim downgraded the stock from Buy to Neutral.</li>
<li>Calliditas Therapeutics AB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALT#NASDAQ">CALT</a>) fell 8.6% to $17.68.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) declined 8% to $2.7050.</li>
<li>Kyverna Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) dipped 7.5% to $14.31.</li>
<li>Civeo Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) fell 7% to $23.25.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38491128/nxp-semiconductors-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-ear">NXP Semiconductors Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>

Intraday Update

Movers

ADXN

ALTM

ANVS

APLD

ATXI

CALT

CAUD

CGEM

CJJD

CLVR

CSSE

CYCC

DAVE

DCPH

ENLV

FLGC

FTEL

FULT

HOPE

HTLF

IBRX

INHD

IONM

ISUN

KYTX

MESO

MPLN

MULN

NUZE

NWGL

OCGN

PAHC

PRME

SLNO

SOFI

SSKN

TCJH

TSLA

ZVSA

Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session

For the full year of 2024, Civeo is maintaining its previously provided Adjusted EBITDA&nbsp;guidance&nbsp;range&nbsp;of&nbsp;$80 million&nbsp;to&nbsp;$90 million and capital expenditure&nbsp;guidance&nbsp;of&nbsp;$30 million&nbsp;to&nbsp;$35 million.

Civeo Maintains FY24 Revenue Guidance Range Of $625M-$700M, Est $653.562M

Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.20) by 75 percent. The company reported quarterly sales of $166.120 million which beat the analyst consensus estimate of $154.726 million by 7.36 percent. This is a 0.88 percent decrease over sales of $167.591 million the same period last year.

Civeo Q1 2024 GAAP EPS $(0.35) Misses $(0.20) Estimate, Sales $166.120M Beat $154.726M Estimate

Civeo Expects FY24 Revenues Of $625M-$700M Vs. 623.11M Estimate, Sees Adjusted EBITDA Of $80M-$90M And Capital Expenditures Of $30M-$35M

Civeo Corporation Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

Civeo Corporation GAAP EPS of -$0.36 misses by $0.34, revenue of $176.34M beats by $7.59M

Civeo Corporation (CVEO) Q3 2024 Earnings Call Transcript

Civeo Corp. ( ($CVEO) ) has realeased its Q3 earnings. Here is a breakdown of the information Civeo Corp. presented to its investors. Civeo Corpora...

Civeo Corp. Reports Q3 2024 Earnings Highlights

Civeo Corporation declares $0.25 dividend

Civeo Corporation: Some Favorable Narratives, But A Challenging Q4 Beckons

Civeo receives 6-year contract extension in Australia

Civeo (CVEO) announced that it was awarded a six-year contract extension with a resources player to provide integrated services at eleven villages ...

Civeo awarded six-year contract extension in Western Australia

In a report released yesterday, Stephen Gengaro from Stifel Nicolaus maintained a Buy rating on Civeo (CVEO – Research Report). The company's share...

Civeo (CVEO) Gets a Buy from Stifel Nicolaus

ARVN

AXTA

BASFY

BIIB

BLKB

BPMC

COCO

CRMD

CRTO

CWEN

EADSF

ENIC

EXTR

FLEX

FVRR

GEHC

GRMN

HESM

INMD

ITCI

IVPAF

LKNCY

NAVI

NBIX

NVCR

OMCL

OPCH

OTIS

PUMP

ROCK

Press Releases

Civeo Reports First Quarter 2024 Results

Civeo Appoints E. Collin Gerry as Chief Financial Officer

Civeo Appoints Andrew S. Fraser as President, Canada

Civeo Announces Second Quarter 2024 Earnings Conference Call

Civeo Reports Second Quarter 2024 Results

Civeo Corporation Announces Amendment and Extension to its Credit Agreement

Civeo Corporation Announces Renewal of Share Repurchase Authorization

Civeo Announces Third Quarter 2024 Earnings Conference Call

Civeo Reports Third Quarter 2024 Results

Civeo Announces a Six-Year A$1.4 Billion Integrated Services Contract Renewal with Expanded Scope in Australia

Comments

Civeo

空売り

Civeo (NYSE:CVEO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル